Independent · Beginner-Friendly · Data-Driven
2 articles found
Biosimilars explained for investors: how they differ from generics, the US$300bn patent cliff, and which Indian companies stand to win.
A beginner-friendly, investor-first guide to biologics: what they are, how they're made in living cells, why they're so expensive and hard to copy, and why that matters for pharma investors.
